Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 1/2024

30.10.2023 | Review Article

Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives

verfasst von: Mónica Munera-Campos, Jose Manuel Carrascosa

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Hormonal and immunologic changes during pregnancy can contribute to the development of different dermatoses, the most common of which is atopic eruption of pregnancy (AEP). Of atopic dermatitis (AD) cases during pregnancy, 80% are new-onset presentations, while 20% represent recurrences or exacerbations of preexisting disease. Evidence on the effects of previous AD on fertility is limited. Different factors influence women’s desire to conceive in this setting, and it has been hypothesized that barrier defects and systemic inflammation could contribute to biologic infertility, although more data are needed. Clinical practice suggests a tendency toward undertreatment in pregnant woman due to concerns about potential effects on obstetric and fetal outcomes. However, pregnant women should be offered adequate and safe treatments, preferably on an individual basis. The aim of this review was to summarize the evidence on disease course in pregnant women with AD and the challenges associated with its diagnosis and management. We also review the current evidence on the use of conventional and novel systemic therapies for AD in this population.
Literatur
1.
Poole JA, Claman HN. Immunology of pregnancy. Implications for the mother. Clin Rev Allergy Immunol. 2004;26:161–70.PubMedCrossRef
2.
Chavan AR, Griffith OW, Wagner GP. The inflammation paradox in the evolution of mammalian pregnancy: turning a foe into a friend. Curr Opin Genet Dev. 2017;47:24–32.PubMedCrossRef
3.
Kanda N, Hoashi T, Saeki H. The roles of sex hormones in the course of atopic dermatitis. Int J Mol Sci. 2019;20(19):4660.
4.
Polese B, Gridelet V, Araklioti E, Martens H, Perrier d’Hauterive S, Geenen V. The endocrine milieu and CD4 T-lymphocyte polarization during pregnancy. Front Endocrinol (Lausanne). 2014;5:106.PubMedPubMedCentralCrossRef
5.
6.
Miyaura H, Iwata M. Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J Immunol. 2002;168:1087–94.PubMedCrossRef
7.
Barankin B, Silver SG, Carruthers A. The skin in pregnancy. J Cutan Med Surg. 2002;6:236–40.PubMedCrossRef
8.
Danesh M, Pomeranz MK, McMeniman E, Murase JE. Dermatoses of pregnancy: nomenclature, misnomers, and myths. Clin Dermatol. 2016;34:314–9.PubMedCrossRef
9.
Horev A, Shalom G, Weintraub AY, Freud T, Cohen AD. Atopic dermatitis and infertility: a nationwide retrospective cohort study. Dermatology. 2022;238:313–9.PubMedCrossRef
10.
Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35:283–9.PubMedCrossRef
11.
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73:1284–93.PubMedCrossRef
12.
13.
Arslan M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril. 2005;84:555–69.PubMedCrossRef
14.
Finelli R, Leisegang K, Finocchi F, De Masi S, Agarwal A, Damiani G. The impact of autoimmune systemic inflammation and associated medications on male reproductive health in patients with chronic rheumatological, dermatological, and gastroenterological diseases: a systematic review. Am J Reprod Immunol. 2021;85: e13389.PubMedCrossRef
15.
Bláfoss J, Hansen AV, Malchau Lauesgaard SS, Ali Z, Ulrik CS. Female asthma and atopy—impact on fertility: a systematic review. J Asthma Allergy. 2019;12:205–11.PubMedPubMedCentralCrossRef
16.
Linares-Gonzalez L, Lozano-Lozano I, Gutierrez-Rojas L, Lozano-Lozano M, Rodenas-Herranz T, Ruiz-Villaverde R. Sexual dysfunction and atopic dermatitis: a systematic review. Life (Basel, Switzerland). 2021;11(12):1314.PubMedPubMedCentral
17.
Gade EJ, Thomsen SF, Lindenberg S, Kyvik KO, Lieberoth S, Backer V. Asthma affects time to pregnancy and fertility: a register-based twin study. Eur Respir J. 2014;43:1077–85.PubMedCrossRef
18.
Sunyer J, Antó JM, Plana E, Janson C, Jarvis D, Kony S, et al. Maternal atopy and changes in parity. Clin Exp Allergy. 2005;35:1028–32.PubMedCrossRef
19.
Karmaus W, Eneli I. Maternal atopy and the number of offspring: is there an association? Pediatr Allergy Immunol. 2003;14:470–4.PubMedCrossRef
20.
Nilsson L, Kjellman NI, Löfman O, Björkstén B. Parity among atopic and non-atopic mothers. Pediatr Allergy Immunol. 1997;8:134–6.PubMedCrossRef
21.
Tata LJ, Hubbard RB, McKeever TM, Smith CJP, Doyle P, Smeeth L, et al. Fertility rates in women with asthma, eczema, and hay fever: a general population-based cohort study. Am J Epidemiol. 2007;165:1023–30.PubMedCrossRef
22.
23.
Dutta S, Sandhu N, Sengupta P, Alves MG, Henkel R, Agarwal A. Somatic-immune cells crosstalk in-the-making of testicular immune privilege. Reprod Sci. 2022;29:2707–18.PubMedCrossRef
24.
Yoshida T, Beck LA, De Benedetto A. Skin barrier defects in atopic dermatitis: from old idea to new opportunity. Allergol Int. 2022;71:3–13.PubMedCrossRef
25.
Yuki T, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y. Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS ONE. 2016;11: e0161759.PubMedPubMedCentralCrossRef
26.
Mikołajczyk M, Wirstlein P, Skrzypczak J. Aberrant claudin-4 transcript levels in eutopic endometrium of women with idiopathic infertility and minimal endometriosis. Ginekol Pol. 2013;84:90–4.PubMedCrossRef
27.
McCabe MJ, Foo CF, Dinger ME, Smooker PM, Stanton PG. Claudin-11 and occludin are major contributors to Sertoli cell tight junction function, in vitro. Asian J Androl. 2016;18:620–6.PubMedCrossRef
28.
Gaetje R, Holtrich U, Engels K, Kissler S, Rody A, Karn T, et al. Differential expression of claudins in human endometrium and endometriosis. Gynecol Endocrinol. 2008;24:442–9.PubMedCrossRef
29.
30.
Yang X-F, Fu C, Liu Y-Q, Liu R-S, Feng H, Huang R-Y, et al. Expression of CLAUDIN-11 in the testicular tissue of the patient with non-obstructive azoospermia and its clinical significance. Zhonghua Nan Ke Xue. 2018;24:221–5.PubMed
31.
Kong BY, Immaneni S, Paller AS, Xu S. Potential impact of biologics and emerging therapies for psoriasis and atopic dermatitis on future fertility: reassurance to patients but more data are needed. J Am Acad Dermatol. 2017;77(4):758–63.PubMedCrossRef
32.
Roca A, Bojang A, Camara B, Oluwalana C, Lette K, West P, et al. Maternal colonization with Staphylococcus aureus and Group B streptococcus is associated with colonization in newborns. Clin Microbiol Infect. 2017;23:974–9.PubMedPubMedCentralCrossRef
33.
Hamann CR, Egeberg A, Wollenberg A, Gislason G, Skov L, Thyssen JP. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. J Eur Acad Dermatol Venereol. 2019;33:577–87.PubMedCrossRef
34.
Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol. 2017;17:469–82.PubMedCrossRef
35.
Gnainsky Y, Granot I, Aldo P, Barash A, Or Y, Mor G, et al. Biopsy-induced inflammatory conditions improve endometrial receptivity: the mechanism of action. Reproduction. 2015;149:75–85.PubMedCrossRef
36.
37.
Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010;63:601–10.PubMedCrossRef
38.
Lindström TM, Bennett PR. The role of nuclear factor kappa B in human labour. Reproduction. 2005;130:569–81.PubMedCrossRef
39.
Grobe W, Peng W, Allam J-P, Yu C-F, Novak N. Androgens have an anti-inflammatory effect on human basophils in vitro. Allergy. 2020;75(4):992–4.PubMedCrossRef
40.
Roved J, Westerdahl H, Hasselquist D. Sex differences in immune responses: hormonal effects, antagonistic selection, and evolutionary consequences. Horm Behav. 2017;88:95–105.PubMedCrossRef
41.
Cho S, Kim HJ, Oh SH, Park CO, Jung JY, Lee KH. The influence of pregnancy and menstruation on the deterioration of atopic dermatitis symptoms. Ann Dermatol. 2010;22:180–5.PubMedPubMedCentralCrossRef
42.
Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol. 2006;54:395–404.PubMedCrossRef
43.
Koutroulis I, Papoutsis J, Kroumpouzos G. Atopic dermatitis in pregnancy: current status and challenges. Obstet Gynecol Surv. 2011;66:654–63.PubMedCrossRef
44.
Vaughan Jones SA, Hern S, Nelson-Piercy C, Seed PT, Black MM. A prospective study of 200 women with dermatoses of pregnancy correlating clinical findings with hormonal and immunopathological profiles. Br J Dermatol. 1999;141:71–81.PubMedCrossRef
45.
46.
Lin Y-C, Wen H-J, Lee Y-L, Guo YL. Are maternal psychosocial factors associated with cord immunoglobulin E in addition to family atopic history and mother immunoglobulin E? Clin Exp Allergy. 2004;34:548–54.PubMedCrossRef
47.
Løken MO, Jeansson S, Jenum PA, Eskild A. Serum level of immunoglobulin E during pregnancy—does offspring sex matter? Paediatr Perinat Epidemiol. 2010;24:75–8.PubMedCrossRef
48.
Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131:383–96.PubMedCrossRef
49.
Roth MM, Cristodor P, Kroumpouzos G. Prurigo, pruritic folliculitis, and atopic eruption of pregnancy: facts and controversies. Clin Dermatol. 2016;34:392–400.PubMedCrossRef
50.
Balakirski G, Novak N. Atopic dermatitis and pregnancy. J Allergy Clin Immunol. 2022;149:1185–94.PubMedCrossRef
51.
Rudolph CM, Al-Fares S, Vaughan-Jones SA, Müllegger RR, Kerl H, Black MM. Polymorphic eruption of pregnancy: clinicopathology and potential trigger factors in 181 patients. Br J Dermatol. 2006;154:54–60.PubMedCrossRef
52.
Regnier S, Fermand V, Levy P, Uzan S, Aractingi S. A case-control study of polymorphic eruption of pregnancy. J Am Acad Dermatol. 2008;58(63):67.
53.
Montagnon CM, Tolkachjov SN, Murrell DF, Camilleri MJ, Lehman JS. Subepithelial autoimmune blistering dermatoses: clinical features and diagnosis. J Am Acad Dermatol. 2021;85:1–14.PubMedCrossRef
54.
Kolodny RC. Herpes gestationis. A new assessment of incidence, diagnosis, and fetal prognosis. Am J Obstet Gynecol. 1969;104:39–45.PubMedCrossRef
55.
Hallaji Z, Mortazavi H, Ashtari S, Nikoo A, Abdollahi M, Nasimi M. Pemphigoid gestationis: clinical and histologic features of twenty-three patients. Int J Womens Dermatol. 2017;3:86–90.PubMedCrossRef
56.
Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol. 2018;231:180–7.PubMedCrossRef
57.
Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33:1644–59.PubMedCrossRef
58.
59.
Coopman S, Degreef H, Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol. 1989;121:27–34.PubMedCrossRef
60.
Chi C-C, Kirtschig G, Aberer W, Gabbud J-P, Lipozenčić J, Kárpáti S, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J Dermatol. 2011;165:943–52.PubMedCrossRef
61.
Chi C-C, Wang S-H, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015(10); p. CD007346.
62.
Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000;70:1718–21.PubMedCrossRef
63.
Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol. 2005;53:602–9.PubMedCrossRef
64.
Undre NA, Moloney FJ, Ahmadi S, Stevenson P, Murphy GM. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2009;160:665–9.PubMedCrossRef
65.
Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol. 2015;8:511–20.PubMedPubMedCentralCrossRef
66.
Zhang M, Goyert G, Lim HW. Folate and phototherapy: what should we inform our patients? J Am Acad Dermatol. 2017;77:958–64.PubMedCrossRef
67.
Wapner RJ, Sorokin Y, Mele L, Johnson F, Dudley DJ, Spong CY, et al. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med. 2007;357:1190–8.PubMedCrossRef
68.
Chin S-OS, Brodsky NL, Bhandari V. Antenatal steroid use is associated with increased gastroesophageal reflux in neonates. Am J Perinatol. 2003;20:205–13.PubMedCrossRef
69.
Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol. 2008;26:19–23.PubMedCrossRef
70.
Moretti ME, Caprara D, Coutinho CJ, Bar-Oz B, Berkovitch M, Addis A, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol. 2003;111:479–83.PubMedCrossRef
71.
Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010;63:944–9.CrossRef
72.
Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71:1051–5.PubMedCrossRef
73.
Perales-Puchalt A, Vila Vives JM, López Montes J, Diago Almela VJ, Perales A. Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison. J Matern Fetal Neonatal Med. 2012;25:1363–6.PubMedCrossRef
74.
Bae Y-SC, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:459–77.PubMedCrossRef
75.
Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:15–22.PubMedCrossRef
76.
Brown SM, Aljefri K, Waas R, Hampton P. Systemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluid. J Dermatolog Treat. 2019;30:2–18.PubMedCrossRef
77.
Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.PubMedCrossRef
78.
Napolitano M, Ruggiero A, Fontanella G, Fabbrocini G, Patruno C. New emergent therapies for atopic dermatitis: a review of safety profile with respect to female fertility, pregnancy, and breastfeeding. Dermatol Ther. 2021;34: e14475.PubMedCrossRef
79.
Costanzo G, Firinu D, Losa F, Deidda M, Barca MP, Del Giacco S. Baricitinib exposure during pregnancy in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X19899296.PubMedPubMedCentralCrossRef
80.
81.
82.
83.
Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et al. J Eur Acad Dermatol Venereol. 2023;37(6):1135–48.PubMedCrossRef
84.
Pfaller B, José Yepes-Nuñez J, Agache I, Akdis CA, Alsalamah M, Bavbek S, et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. Allergy Denmark. 2021;76:71–89.CrossRef
85.
Ramos LC, Namazy J. Monoclonal antibodies (biologics) for allergic rhinitis, asthma, and atopic dermatitis during pregnancy and lactation. Immunol Allergy Clin N Am. 2023;43:187–97.CrossRef
86.
87.
88.
Khamisy-Farah R, Damiani G, Kong JD, Wu J-H, Bragazzi NL. Safety profile of dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBaseTM). Eur Rev Med Pharmacol Sci Italy. 2021;25:5448–51.
89.
Lobo Y, Lee RC, Spelman L. Atopic dermatitis treated safely with dupilumab during pregnancy: a case report and review of the literature. Case Rep Dermatol. 2021;13(2):248–56.PubMedPubMedCentralCrossRef
90.
Escolà H, Figueras-Nart I, Bonfill-Orti M, Coll Puigserver N, Martin-Santiago A, Rodríguez Serna M, et al. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: clinical experience in 13 patients. J Eur Acad Dermatol Venereol. 2023;37(9):e1156-60
91.
Akuffo-Addo E, Nicholas MN, Lansang P. Reported pregnancy outcomes in women with severe atopic dermatitis treated with dupilumab: a systematic review. J Cutan Med Surg. 2023;27(2):177–178.CrossRef
92.
Middleton PG, Gade EJ, Aguilera C, MacKillop L, Button BM, Coleman C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55(2):1901208.PubMedCrossRef
Metadaten
Titel
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives
verfasst von
Mónica Munera-Campos
Jose Manuel Carrascosa
Publikationsdatum
30.10.2023
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 1/2024
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-023-00821-4

Weitere Artikel der Ausgabe 1/2024

American Journal of Clinical Dermatology 1/2024 Zur Ausgabe

Review Article

Photodynamic Therapy in Treating a Subset of Basal Cell Carcinoma: Strengths, Shortcomings, Comparisons with Surgical Modalities, and Potential Role as Adjunctive Therapy

Original Research Article

Relationship of Histopathologic Parameters and Gene Expression Profiling in Malignant Melanoma

Correction

Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

Correction

Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids

Review Article

Treat-to-Target in Atopic Dermatitis

Original Research Article

AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise